However, ABT-737 does not target Mcl-1 and inhibiting Mcl-1 and/or inducing its BH3-only partners (Bim, Puma and Noxa) represent a rational strategy to sensitize ovarian carcinoma cells to ABT-737 10,11. This evidence concerns the gene MCL1 and ovarian carcinoma.